Lee Hambright
Stock Analyst at Bernstein
(2.10)
# 3,498
Out of 5,241 analysts
42
Total ratings
43.75%
Success rate
-3.44%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Outperform | $56 → $54 | $36.19 | +49.21% | 2 | May 7, 2026 | |
| PODD Insulet | Maintains: Outperform | $330 → $200 | $147.46 | +35.63% | 4 | May 7, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $154 → $125 | $84.47 | +47.98% | 7 | Jan 23, 2026 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $740 → $750 | $421.12 | +78.10% | 4 | Jan 23, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $97 → $99 | $83.70 | +18.28% | 2 | Jan 9, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Market Perform | $18 → $25 | $12.82 | +95.01% | 2 | Jan 9, 2026 | |
| SYK Stryker | Maintains: Outperform | $450 → $465 | $306.76 | +51.58% | 4 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Outperform | $111 → $112 | $76.15 | +47.08% | 4 | Jan 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Market Perform | $193 → $208 | $226.71 | -8.25% | 6 | Jan 9, 2026 | |
| DXCM DexCom | Maintains: Outperform | $84 → $86 | $61.63 | +39.54% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $100 | $52.68 | +89.83% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $81.38 | +65.89% | 3 | Mar 16, 2022 |
Medline
May 7, 2026
Maintains: Outperform
Price Target: $56 → $54
Current: $36.19
Upside: +49.21%
Insulet
May 7, 2026
Maintains: Outperform
Price Target: $330 → $200
Current: $147.46
Upside: +35.63%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $154 → $125
Current: $84.47
Upside: +47.98%
Intuitive Surgical
Jan 23, 2026
Maintains: Outperform
Price Target: $740 → $750
Current: $421.12
Upside: +78.10%
Zimmer Biomet Holdings
Jan 9, 2026
Maintains: Market Perform
Price Target: $97 → $99
Current: $83.70
Upside: +18.28%
Tandem Diabetes Care
Jan 9, 2026
Maintains: Market Perform
Price Target: $18 → $25
Current: $12.82
Upside: +95.01%
Stryker
Jan 9, 2026
Maintains: Outperform
Price Target: $450 → $465
Current: $306.76
Upside: +51.58%
Medtronic
Jan 9, 2026
Maintains: Outperform
Price Target: $111 → $112
Current: $76.15
Upside: +47.08%
Johnson & Johnson
Jan 9, 2026
Maintains: Market Perform
Price Target: $193 → $208
Current: $226.71
Upside: -8.25%
DexCom
Jan 9, 2026
Maintains: Outperform
Price Target: $84 → $86
Current: $61.63
Upside: +39.54%
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $52.68
Upside: +89.83%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $81.38
Upside: +65.89%